Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HTMC 0435

Next Previous
Drug Profile

HTMC 0435

Alternative Names: HTMC-0435

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Huilun Pharmaceutical
  • Developer Shanghai Huilun Pharmaceutical; Shanghai Yidian Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I/II Small cell lung cancer

Most Recent Events

  • 28 May 2025 Adverse event and efficacy data from the phase I/II study of Small cell lung carcinoma presented at the 61st Annual Meeting of the American Society of Clinical OncologySession 2025 (ASCO-2025)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO, Tablet)
  • 15 Feb 2023 Shanghai Huilun Pharmaceutical in collaboration with Shanghai Shanghai Yidian Pharmaceutical plans a phase Ib/II trial for Small cell lung cancer in (Combination therapy, Second line therapy, Late-stage disease) in China (PO) in February 2023 (NCT05728619)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top